Every 8-K that Anika Therapeutics Inc (ANIK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ANIK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANIK filings page.
Anika Therapeutics reported strong second-quarter 2026 results, with total revenue up 16% year over year to $32.6 million. Commercial Channel revenue grew 17% to a record $13.9 million and OEM Channel revenue rose 14% to $18.7 million. Gross profit increased to $21.2 million and gross margin expanded to 65%, helped by higher volumes, increased production and a favorable sales mix, while operating expenses were roughly flat at $18.3 million.
Income from continuing operations was $3.3 million, a 10% margin, and adjusted EBITDA reached $7.1 million, its highest level since 2020, with a 22% margin. Cash and equivalents were $38.4 million at June 30, 2026. Based on this performance, Anika raised 2026 guidance, now expecting total revenue growth of 5%–10% and an adjusted EBITDA margin of 13%–17%, and revised 2027 guidance under a new practice that excludes unapproved products, lowering Commercial Channel growth expectations to 5%–15%. The company also highlighted ongoing FDA review of the Hyalofast PMA and progress toward an NDA filing for Cingal.
Anika Therapeutics, Inc. entered into a Fifth Amendment to its Credit Agreement with Bank of America, N.A. on July 10, 2026. The Amended Agreement provides a $50.0 million senior revolving line of credit with a maturity date of July 10, 2031.
Subject to specified conditions and lender approval, Anika may request up to an additional $50.0 million in commitments for a maximum aggregate commitment of $100.0 million. Borrowings bear interest at SOFR plus 0.25%–1.25%, based on Anika’s consolidated leverage ratio. A 0.20%–0.30% annual commitment fee applies to the unused facility, payable quarterly in arrears. Loan origination costs are amortized over the five-year term. The facility includes customary covenants and events of default, with financial covenants tied to leverage and interest coverage, and is secured by a first priority lien on substantially all assets other than certain intangible assets.
Anika Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders and approvals of equity compensation plan amendments. Stockholders approved a revised omnibus incentive plan that increases the common stock reserved under the plan by 350,000 shares to 6,110,000 shares and allows all of these shares to be granted as incentive stock options. They also approved an amendment to the 2021 Employee Stock Purchase Plan, doubling its share reserve from 200,000 to 400,000 shares.
All three Class III director nominees were elected to terms ending at the 2029 annual meeting, the advisory say-on-pay vote passed, and Deloitte & Touche LLP was ratified as independent auditor for the fiscal year ending December 31, 2026. At the meeting, 11,195,667 of 13,305,624 eligible shares were represented, reflecting 84.14% of the voting power.
Anika Therapeutics reported first quarter 2026 revenue of $29.6 million, up 13% from $26.2 million a year earlier, driven by OEM Channel revenue of $17.0 million, up 14%, and Commercial Channel revenue of $12.6 million, up 12%.
Gross margin improved to 64.2% from 56.1% as gross profit rose to $19.0 million. Operating expenses increased to $24.5 million, including $4.9 million of one-time severance costs. The company recorded a GAAP loss from continuing operations of $5.1 million, or $0.37 per diluted share.
Non-GAAP results showed adjusted net income from continuing operations of $3.8 million, or $0.27 per diluted share, and adjusted EBITDA of $4.3 million versus $0.1 million a year earlier. Cash and cash equivalents were $41.0 million as of March 31, 2026.
The company reaffirmed its 2026 guidance, with total revenue expected between $114 million and $122.5 million and adjusted EBITDA margin between 5% and 10%. Anika also completed its previously announced $15 million 10b5-1 share repurchase at an average price of $10.76 per share. Separately, directors William Jellison and Glenn Larsen will step down at the 2026 annual meeting, and the board will be reduced from nine to seven members; their resignations are not due to any disagreement with the company.
Anika Therapeutics reported fourth quarter and full-year 2025 results and outlined leadership transition plans for its General Counsel. Q4 2025 revenue was $30.6 million, essentially flat year over year, with gross margin expanding to 63%. Commercial Channel revenue grew 22% while OEM Channel revenue declined 12%.
For full-year 2025, revenue was $112.8 million, down 6% from 2024, but gross margin improved to 57%. The company generated $11.2 million in operating cash flow and $4.4 million in free cash flow, and reduced its net loss to $10.9 million from $56.4 million in 2024. Adjusted EBITDA was $5.3 million in 2025 versus $15.5 million in 2024.
Anika continued a $15 million Rule 10b5-1 share repurchase program, funding $10.7 million to date and expecting completion in the second quarter of 2026. The company received an FDA response to its Hyalofast PMA in January 2026 and is preparing follow-up submissions, while progressing remaining requirements for the Cingal NDA. Separately, Anika entered a Transition Agreement under which Executive Vice President, General Counsel and Corporate Secretary David Colleran will remain in his role through May 1, 2026, with continued salary, benefits, and equity vesting, and will receive separation benefits pursuant to his Executive Retention Agreement in exchange for a general release of claims.
Anika Therapeutics, Inc. filed a report detailing a leadership transition while reaffirming its guidance for the year ended December 31, 2025, including expectations that Adjusted EBITDA margin will range from positive 3% to negative 3% of revenue.
The company announced that President and Chief Executive Officer Cheryl R. Blanchard will step down from the CEO role effective February 1, 2026, moving to Executive Chair for twelve months, then Special Advisor for six months, and remaining an employee through January 31, 2028. Under a transition agreement, she will receive cash severance equal to 18 months of base salary paid over 24 months and continued eligibility for benefits and equity vesting during her service.
Steve Griffin, currently Executive Vice President, Chief Financial Officer and Chief Operating Officer, has been appointed President and Chief Executive Officer effective February 1, 2026 and will also join the Board as a Class III director. His new employment agreement provides a $690,000 annual base salary, a target annual bonus equal to 75% of base salary starting in 2026, and equity awards with a target grant date fair value of $2,450,000 in restricted stock units and stock appreciation rights vesting over three years. Director Susan N. Vogt will resign from the Board effective February 1, 2026 with no reported disagreements, and the company has entered into indemnification agreements with each director.
Anika Therapeutics (ANIK) filed an 8‑K noting it furnished a press release with its financial results for the third quarter ended September 30, 2025. The company states this information is being furnished, not filed, under the Exchange Act. The earnings press release is attached as Exhibit 99.1.
Anika also announced a regulatory milestone for Hyalofast. The company filed the third and final module of its Premarket Approval application for Hyalofast, a resorbable, hyaluronic acid‑based scaffold used with autologous bone marrow aspirate concentrate to treat articular cartilage defects in the knee, and reported results from its U.S. pivotal Phase III FastTRACK trial evaluating Hyalofast. This update is provided via a separate press release attached as Exhibit 99.2.
On 30 Jul 2025, Anika Therapeutics (ANIK) filed a Form 8-K (Item 7.01) to furnish a press release (Exhibit 99.1) announcing top-line results from its U.S. pivotal FastTRACK Phase III study of the Hyalofast cartilage-repair scaffold and providing a program update. No financial figures, efficacy data, or regulatory timelines are included in the filing itself; those details reside in the furnished press release, which is not reproduced here. The information is deemed “furnished,” not “filed,” so it is excluded from Exchange Act liability and will not be automatically incorporated into future SEC filings. Apart from the exhibit list, the 8-K contains no additional disclosures under Items 1–6, and there are no financial statements attached.
Anika Therapeutics held its Annual Meeting on June 20, 2025, with 86.13% shareholder participation (12.35M shares represented). Key outcomes include:
- Board Elections: Three Class II directors elected until 2028 - Cheryl Blanchard, Joseph Capper, and Glenn Larsen, with Capper receiving strongest support (10.5M votes)
- 2017 Omnibus Incentive Plan Amendment: Shareholders approved increasing reserved shares by 475,000 to total 5.76M shares. All shares may be granted as incentive stock options under IRC Section 422
- Other Approvals: Shareholders ratified Deloitte & Touche as independent auditor (12.07M votes in favor) and approved executive compensation in advisory vote (8.37M votes in favor)
The meeting demonstrated strong shareholder engagement, though some proposals like executive compensation and incentive plan amendment faced notable opposition with over 2.5M votes against each.